LRLiqun Ren

Liqun Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liqun Ren has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Genshan Ma

    Department of Cardiology, Zhongda Hospital, Southeast University, Nanjing, China

    2 shared publications
  • Kongbo Zhu

    Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, Jiangsu, China

    2 shared publications
  • Li An

    Department of Geriatrics, Zhongda Hospital, Southeast University, Nanjing, PR China

    2 shared publications
  • Linglin Qian

    Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, Jiangsu, China

    2 shared publications
  • Naifeng Liu

    School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Affiliated Zhongda Hospital, Southeast University, Nanjing 210009, China

    2 shared publications
  • Yanshan Lin

    Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, Jiangsu, China

    2 shared publications

Latest Publications

  • From Mechanism to Therapy: Establishing an Integrated Framework for the Regulation and Intervention of Matrix Vesicles in Vascular Calcification

    by Mincheng Yu, Jingzheng Chen, Xinyue Wang, Ling Chen, Xiaomei Ren, Mayibai Mushajiang, Liqun Ren, Zhongqun Wang

  • The role of shear wave elastography in diagnosing sarcopenia in patients with type 2 diabetes

    by Li An, Jinjun Shi, Ye Pan, Yu Ding, Wei Gao, Liqun Ren, Jing Wang, Yao Wang

    Objective To assess the utility of shear wave elastography (SWE) for the diagnosis of sarcopenia in individuals with type 2 diabetes (T2D). Methods In this study, we measured the shear wave velocity (SWV) in the medial gastrocnemius muscle (GCM) in both the relaxed and stretched states via SWE. The study involved 273 T2D patients at Zhongda Hospital Southeast University and was conducted between March 2022 and June 2023. In addition to the SWV, we evaluated the appendicular skeletal muscle mass index (ASMI), muscle strength as measured by handgrip strength, and gait speed as measured by the 6-meter walk test. We analyzed the relationships between conventional sarcopenia indicators and SWV variables and developed diagnostic models based on significant predictors. Results The age of the patients ranged from 60 to 72 years, with a median age of 66 years, and nearly half (48.0%, n = 131) were female. On the basis of the 2019 criteria set by the Asian Working Group for Sarcopenia (AWGS), the participants were categorized into nonsarcopenia (212, 77.7%) and sarcopenia (61, 22.3%) groups. There was a notable difference in the SWV between those with and without sarcopenia (p < 0.01). A robust positive correlation was identified between traditional sarcopenia indicators and the SWVbent. A logistic regression model incorporating BMI, ASMI, SWVstraight, and SWVbent demonstrated high sensitivity (96.7%) and specificity (82.5%), with an AUC of 0.946. Conclusion Our findings suggest that SWE could be a valuable tool for the objective assessment of sarcopenia in T2D patients. However, additional large-scale, multicenter, and prospective studies are warranted to validate these results.


  • Insulin secretion impairment induced by rosuvastatin partly though autophagy in INS‐1E cells

    by Linglin Qian, Kongbo Zhu, Yanshan Lin, Li An, Feiyang Huang, Yuyu Yao, Liqun Ren

    Statins are used extensively for the clinical treatment of cardiovascular diseases. Recent studies suggest that statins increase the risk of new‐onset diabetes mellitus (NODM). However, the mechanisms of statin‐induced NODM remain unclear. The present study investigated the effects of autophagy on insulin secretion impairment induced by rosuvastatin (RS) in rat insulinoma cells (INS‐1E) cells. INS‐1E cells were cultured and treated with RS at different concentrations (0.2–20 μM) for 24 h. Insulin secretion in INS‐1E cells was detected by enzyme‐linked immunosorbent assay, and the co‐localization of microtubule‐associated protein light chain 3 (LC3) and lysosome‐associated membrane protein 2 (LAMP‐2) was observed by immunofluorescence staining. Western blotting was used to assess the conversion of LC3 and p62. The results showed that the insulin secretion and cell viability decrease induced by RS treatment for 24 h occurred in a dose‐dependent manner in INS‐1E cells. RS significantly inhibited the expression of LC3‐II but increased the protein expression of p62. Simultaneously, RS diminished the co‐localization of LC3‐II and LAMP‐2 fluorescence signals. These results suggested that RS‐inhibited autophagy in INS‐1E cells. Rapamycin, an autophagy agonist, reversed the insulin secretion and cell viability suppression induced by RS in INS‐1E cells. RS also decreased the phosphorylation of the mammalian target of rapamycin (mTOR). The results indicated that RS impairs insulin secretion in INS‐1E cells, which may be partly due to the inhibition of autophagy via an mTOR‐dependent pathway.


  • Open Access

    Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells

    by Kongbo Zhu, Linglin Qian, Yanshan Lin, Li An, Guangjian Mu, Genshan Ma, Liqun Ren

    Increasing evidence shows that statins increase the risk of new-onset diabetes mellitus, but the exact mechanism is not clearly known. Free fatty acid receptor 1 (FFA1) has been recognized to mediate insulin secretion, and pioglitazone has direct effects on glucose-stimulated insulin secretion in addition to the reversion of insulin resistance. In this study, we found that atorvastatin decreased potassium-stimulated insulin secretion and inhibited the expression of FFA1, PDX-1, and BETA2/NeuroD in INS-1 cells. Further study demonstrated that pioglitazone prevented the impairment of insulin secretion induced by atorvastatin and enhanced the expression of FFA1, PDX-1, and BETA2/NeuroD reduced by atorvastatin in INS-1 cells. In addition, the preventive effect of pioglitazone on atorvastatin-induced impairment of insulin secretion and the enhancement of the expression of PDX-1 and BETA2/NeuroD was abolished by knockdown of FFA1 using siRNA or the PLC inhibitor, U-73122, respectively. Ultimately, FFA1 may mediate the atorvastatin-induced pancreatic β-cell dysfunction and pioglitazone may ameliorate this deleterious effect through the upregulation of FFA1 expression.


  • Open Access

    Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells

    by Xiaomei Ren, Liqun Ren, Qin Wei, Hua Shao, Long Chen, Naifeng Liu

    Advanced glycation end-products (AGEs) are elevated under diabetic conditions and associated with insulin resistance, endothelial dysfunction and vascular inflammation in humans. It has been demonstrated that AGEs evoke oxidative and inflammatory reactions in endothelial cells through the interaction with a receptor for AGEs (RAGE). Here, we aimed to identify the cellular mechanisms by which AGEs exacerbate the endothelial dysfunction in human coronary artery endothelial cells (HCAECs). 30 type 2 diabetic patients with or without coronary artery atherosclerosis were recruited for this study. Plasma levels of AGE peptides (AGE-p) were analyzed using flow injection assay. Endothelial function was tested by brachial artery flow-mediated vasodilatation (FMD). Further investigations were performed to determine the effects and mechanisms of AGEs on endothelial dysfunction in HCAECs. AGE-p was inversely associated with FMD in diabetic patients with coronary artery atherosclerosis in our study. After treated with AGEs, HCAECs showed significant reductions of eNOS mRNA and protein levels including eNOS and phospho-eNOS Ser1177, eNOS mRNA stability, eNOS enzyme activity, and cellular nitric oxide (NO) levels, whereas superoxide anion production was significantly increased. In addition, AGEs significantly decreased mitochondrial membrane potential, ATP content and catalase and superoxyde dismutase (SOD) activities, whereas it increased NADPH oxidase activity. Treatment of the cells with antioxidants SeMet, SOD mimetic MnTBAP and mitochondrial inhibitor thenoyltrifluoroacetone (TTFA) effectively blocked these effects induced by AGEs. AGEs also increased phosphorylation of the mitogen-activated protein kinases p38 and ERK1/2, whereas the specific inhibitors of p38, ERK1/2, and TTFA effectively blocked AGEs-induced reactive oxygen species production and eNOS downregulation. AGEs cause endothelial dysfunction by a mechanism associated with decreased eNOS expression and increased oxidative stress in HCAECs through activation of p38 and ERK1/2.


  • Open Access

    Demethoxycurcumin Preserves Renovascular Function by Downregulating COX‐2 Expression in Hypertension

    by Yingjuan Li, Danyang Tian, Chunhua Zhu, Liqun Ren

    Hypertension‐associated endothelial dysfunction is largely due to the exaggerated vasoconstrictor generation by cyclooxygenase‐2 (COX‐2). COX‐2 is induced under inflammatory condition. Demethoxycurcumin (DMC) is a major component of Curcuma longa L, which possesses anti‐inflammatory action. This study aimed to examine whether DMC protects endothelial function in hypertension by modulating COX‐2. Changes in isometric tension showed that in vivo and ex vivo treatment with DMC rescued the attenuated endothelium‐dependent relaxations (EDRs) and elevated endothelium‐dependent contractions (EDCs) in the renal arteries of SHR, which were also corrected by acute usage of the COX‐2 inhibitor celecoxib. The restoration of renovascular activity by DMC was accompanied by the normalization of COX‐2 expression. The enhanced COX‐2 expression observed in the renal arteries of hypertensive patients was suppressed by incubation of excised arteries with DMC for 12 hrs. In the renal arteries of Wistar‐Kyoto rats (WKY), DMC prevented the endothelial dysfunction caused by angiotensin II. The reduction in the generation of nitric oxide (NO) and expression of eNOS phosphorylation (Ser1177) in human umbilical vein endothelial cells caused by angiotensin II (Ang II) were restored by DMC or celecoxib. Our findings suggest that DMC may decrease COX‐2 expression and improve endothelial function in hypertension.


  • Open Access

    Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats

    by Jing Lu, Yu-Yu Yao, Qi-Ming Dai, Gen-Shan Ma, Shu-Feng Zhang, Lei Cao, Li-Qun Ren, Nai-Feng Liu

    Background: Recent studies revealed that erythropoietin (EPO) has tissue-protective effects in the heart by increasing vascular endothelial growth factor (VEGF) expression and attenuating myocardial fibrosis in ischemia models. In this study, we investigated the effect of EPO on ventricular remodeling and blood vessel growth in diabetic rats. Methods: Male SD rats were randomly divided into 3 groups: control rats, streptozotocin (STZ)-induced diabetic rats, and diabetic rats treated with 1000 U/kg EPO by subcutaneous injection once per week. Twelve weeks later, echocardiography was conducted, and blood samples were collected for counting of peripheral blood endothelial progenitor cells (EPCs). Myocardial tissues were collected, quantitative real-time PCR (RT-PCR) was used to detect the mRNA expression of VEGF and EPO-receptor (EPOR), and Western blotting was used to detect the protein expression of VEGF and EPOR. VEGF, EPOR, transforming growth factor beta (TGF-β), and CD31 levels in the myocardium were determined by immunohistochemistry. To detect cardiac hypertrophy, immunohistochemistry of collagen type I, collagen type III, and Picrosirius Red staining were performed, and cardiomyocyte cross-sectional area was measured. Results: After 12 weeks STZ injection, blood glucose increased significantly and remained consistently elevated. EPO treatment significantly improved cardiac contractility and reduced diastolic dysfunction. Rats receiving the EPO injection showed a significant increase in circulating EPCs (27.85 ± 3.43%, P < 0.01) compared with diabetic untreated animals. EPO injection significantly increased capillary density as well as EPOR and VEGF expression in left ventricular myocardial tissue from diabetic rats. Moreover, EPO inhibited interstitial collagen deposition and reduced TGF-β expression. Conclusions: Treatment with EPO protects cardiac tissue in diabetic animals by increasing VEGF and EPOR expression levels, leading to improved revascularization and the inhibition of cardiac fibrosis.


  • Open Access

    Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro

    by Liqun Ren, Naifeng Liu, Hong Zhi, Yingjuan Li, Yanzhi Li, Rining Tang, Zulong Sheng

    The peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone has been suggested to exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARγ agonists is not fully understood. The present study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.


  • The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin‐angiotensin system in diet‐induced hypercholesterolemic rats

    by Liqun Ren, Yingjuan Li, Yanzhi Li, Rining Tang, Dingbo Hu, Zulong Sheng, Naifeng Liu

    Cardiac hypertrophy is not only an adaptational state before heart failure but also is an independent risk factor for ischemia, arrhythmia, and sudden death. However, the direct effects of hypercholesterolemia on the myocardium and mechanisms are not completely understood. It has been demonstrated that peroxisome proliferator‐activated receptor‐γ (PPARγ) ligand agonists attenuate cardiac hypertrophy through anti‐inflammatory effects. The present study investigated the effects of PPARγ agonists on hypercholesterolemia‐dependent, renin‐angiotensin‐system‐related cardiac hypertrophy. The findings showed that left ventricular hypertrophy, eminent cardiomyocyte hypertrophy, and lipid deposits in myocardium were observed in the rats fed a cholesterol‐rich diet for 6 months, while these characteristic pathological alterations and the increase in angiotensin II (ANG II) level and over‐expression of angiotensin II type 1 receptor (AT1R) in the left ventricular tissues induced by the cholesterol‐rich diet were significantly suppressed to equal extents by rosiglitazone and irbesartan. In contrast, expression of angiotensin II type 2 receptor (AT2R) was upregulated by these two drugs. In addition, lipid metabolism was markedly improved. The above findings suggest that the cardioprotection of the PPARγ agonist against cardiac hypertrophy evoked by hypercholesterolemia in rats is mediated partially by the improvement of lipid profile, the reduction of ANG II level in the local tissue along with the downregulation of AT1R expression, and upregulation of AT2R expression. Copyright © 2009 John Wiley & Sons, Ltd.